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Studies have revealed a consistent set of genetic alterations, such
as activation of proto-oncogenes and inactivation of tumour
suppressor genes, in a variety of human malignancies. Because of
the variety of histological types and mutagenetic substances, the
molecular pathogenesis of gastric cancers is largely unknown. It is
known, however, that there is some involvement of mutations 
in p53 (Tamura et al, 1991) and E (epithelial)-cadherin genes
(Tamura et al, 1996a), as well as microsatellite instability (MSI)
due to mismatch repair deficiency (Tamura, 1995). Loss of
heterozygosity (LOH) studies have suggested the presence of
tumour suppressor genes on several chromosomal arms (Tamura 
et al, 1995, 1996b). However, the few genes that have been
isolated from these regions, such as APC on 5q21 and DPC4
(Smad4) on 18q21, exhibit absent or infrequent mutations in
gastric cancers (Maesawa et al, 1995; Nishizuka et al, 1997). LOH
on chromosome 18q21 is frequently found in gastric cancers
(Uchino et al, 1992; Tamura et al, 1996b; Nishizuka et al, 1998),
and DCC has been postulated to be the major target. However, few
reports have focused on DCC gene mutations and its mutational
status is unknown in gastric cancer, probably because of the length
and complexity of this gene (Fearon et al, 1990). DPC4 (Smad4),
another tumour suppressor gene on 18q21, exhibited frequent
mutations accompanied by LOH in pancreatic cancers (Hahn et al,
1996), but no mutations have been found in gastric cancers
(Nishizuka et al, 1997). 
Aberrant DNA methylation of promoter CpG islands serves 
as an alternative mechanism to coding region mutation for the
inactivation of tumour suppressor or tumour-related genes,
including retinoblastoma (RB), von Hippel-Lindau (VHL), p16,
p15, hMLH1, and E-cadherin (Herman et al, 1996, 1998; Graff 
et al, 1997; Stirzaker et al, 1997). Because gastric cancer displays
the CpG island methylator phenotype (Toyota et al, 1999), and
promoter hypermethylation of p16, hMLH1, and E-cadherin genes
has been detected in gastric cancers (Fleisher et al, 1999; Toyota 
et al, 1999; Tamura et al, 2000), it is possible that DCC may also
be affected by this epigenetic event. 
We investigated sequence mutations, expression, and methyla-
tion status of DCC in primary gastric cancers. We found frequent
loss of DCC expression in relation to hypermethylation but not in
relation to sequence mutations. 
MATERIALS AND METHODS 
Primary gastric cancers 
60 pairs of cancerous and non-cancerous tissues were surgically
obtained from gastric cancer patients (13 differentiated and 17
undifferentiated carcinomas at the early stage, and 11 differenti-
ated and 19 undifferentiated carcinomas at the advanced stage).
These tissues were immediately frozen and stored at –80°C until
analysis. 
Preparation of DNA 
DNA was extracted from the 60 primary gastric cancers and their
corresponding non-cancerous gastric mucosae with SepaGene
(Sankojunyaku, Tokyo, Japan). 
Microsatellite analysis 
LOH was examined using three polymorphic microsatellite
markers, D18S474, D18S46 and DCC, obtained from MapPairs
(Research Genetics, Huntsville, AL) on 18q21. PCR mix contained
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MgCl2, deoxynucleotide triphosphates (each at 200 mM), 2.5 mCi
of [a-32P] dCTP (Amersham, Buckinghamshire, England), primers
(1 mM each per reaction), 0.5 U AmpliTaq Gold™ DNA poly-
merase (PE Applied Biosystems, Foster City, CA) and genomic
DNA (100 ng) in a final volume of 10 ml. Amplification was
carried out in a GeneAmp PCR System 2400 (PE Applied
Biosystems) for 35 cycles (15 s at 95°C, 15 s at appropriate
annealing temperature, then 30 s at 72°C), followed by a final 7-
min extension at 72°C. PCR products were diluted 1:10 in dena-
turing loading buffer [95% formamide, 10 mM EDTA (pH 8.0),
0.02% xylene cyanol FF, and 0.02% bromphenol blue], heated at
95°C for 5 min, placed on ice, and then 1.5 ml were subjected to
electrophoresis. Gels for microsatellite analysis consisted of 6%
polyacrylamide and 7 M urea. Gels were dried and exposed to
Hyperfilm MP autoradiography film (Amersham) for 2–16 h. 
PCR-SSCP and sequencing 
25 pairs of primers, including intron–exon boundaries, were used
to amplify 25 of the 29 DCC exons, which have been described by
Kong et al (1997). PCR conditions and products treatment for
SSCP were the same as described for microsatellite analysis. Gels
for SSCP analysis consisted of 6% polyacrylamide and 5% glyc-
erol. Direct sequencing was performed using a small piece of the
gel containing the shift band detected by SSCP. The gel was
immersed in 50 ml of water, heated at 95°C, and then applied to
PCR under the conditions described above for SSCP except that
PCR was carried out in a volume of 50 ml. The PCR products were
directly loaded onto nondenaturing 2% agarose gels and purified
using QIA quick Gel Extraction Kit (QIAGEN, Tokyo, Japan).
The purified PCR products were sequenced with the dRhodamine
Terminator Cycle Sequencing Kit (PE Applied Biosystems). Gel
electrophoresis, data collection and analysis were done with a
Genetic Analyzer (model 310, PE Applied Biosystems). 
Methylation-specific PCR (MSP) 
DNA methylation status was determined by MSP, as described
previously (Herman et al, 1996). MSP distinguishes unmethylated
from methylated alleles in a given gene based on sequence
changes produced after bisulfite treatment of DNA, which
converts unmethylated, but not methylated cytosines to uracil.
Subsequently, PCR is performed using primers specific to either
methylated or unmethylated DNA. Briefly, 1 mg of DNA was
denatured by treatment with NaOH and modified by sodium bisul-
fite. DNA samples were then purified using Wizard DNA purifica-
tion resin (Promega, Madison, WI), again treated with NaOH,
precipitated with ethanol, and resuspended in water. Since the
sequence of DCC promoter has not been available, we obtained
the sequence of 5¢  flanking region by direct sequencing and
designed the following primers flanking the start codon. The
primers used were 5¢-CGTTGTTCGCGATTTTTGGTTTC-3¢
(–41 to –19 bp from the start codon) and 5¢-ACCGATTACT-
TAAAAATACGCG-3¢ (71 to 92 bp from the start codon) for
methylated (134 bp); and 5¢-GTTGTTGTTGTTTGTGATTTTTG-
GTTTT-3¢ (–46 to –19 bp from the start codon) and 5¢-CCACT-
TACCAATTACTTAAAAATACACA-3¢ (71 to 98 bp from the
start codon) for the unmethylated DNA (145 bp) (Gen Bank acces-
sion No. M32292). The PCR amplified region for methylated and
unmethylated alleles contained 8 CpG dinucleotides, including 3
or 4 CpGs at the primer annealing sites, respectively. PCR was
performed under the same conditions described for microsatellite
analysis except for the final volume of 20 ml. Sss-I methylase-
treated DNA (New England Biolabs, Inc, Beverly, MA) and
normal peripheral blood DNA served as positive and negative
controls after bisulfite-modification, respectively. 10 ml samples of
each PCR reaction product were directly loaded onto nondena-
turing 6% polyacrylamide gels, stained with ethidium bromide,
and visualized under UV illumination. 
Immunohistochemistry 
Paraffin-embedded sections were evaluated immunohistochemi-
cally with a purified mouse anti-human DCC monoclonal antibody
(clone G97–449, Pharmingen, San Diego, CA). Individual tissue
sections of 3 mm were deparaffinized and heated in a 10 mM citric
acid monophosphate buffer (pH 6) for 30 minutes in a 1.35-kW
microwave oven at high power for antigen retrieval. The primary
antibody was used at a dilution of 1:100. Sections were stained by
the immunoperoxidase method with a streptavidin-biotin (SAB)
complex system (Nichirei, Tokyo, Japan). Slides were counter-
stained with methylgreen. Immunoreactivity was judged as posi-
tive when at least 25% of tumour cells were immunoreactive with
the DCC monoclonal antibody. 
Statistics 
Statistical significance of difference was evaluated by Fisher’s
exact test with a criterion of P < 0.05. 
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Figure 1 Microsatellite analysis in primary gastric cancers. Apparent
reduction in intensity of one of two bands in tumour DNA indicates LOH
(arrowheads), and the presence of additional bands in tumour DNA, which
are not seen in normal DNA, indicates MSI (asterisks). T, tumour DNA; N,
corresponding gastric mucosa DNA 
Table 1 Histological type and LOH on 18q21 
Clinical stage and histological type N* LOH**(%) 
Early-differentiated 11 6 (55)a
Early-undifferentiated 14 1 (7)b
Advanced-differentiated 9 2 (22)c
Advanced-undifferentiated 18 8 (44)d
Total 52 17 (33) 
*, number of informative cases; **, number of cases exhibiting LOH on 18q21;
avs. b, bvs. d, P < 0.05; bvs.a+c+d, P < 0.015. RESULTS 
LOH on 18q21 
The frequencies of LOH at each microsatellite marker were 30%
(7/23 informative cases) at D18S474, 29% (10/34) at D18S46 and
23% (5/22) at DCC, respectively. LOH on at least one of the 3
microsatellite markers was detected in 17 (33%) of 52 informative
cases among 60 primary gastric cancers (Figure 1). The other 8
gastric cancers showed homozygosity for all markers. LOH is
significantly less frequent in undifferentiated cancers at the early
stage (7%; 1/14) than in others (42%; 16/38) (P = 0.015) (Table 1). 
DCC mutations 
No somatic mutations were detected in 25 of 29 DCC exons eval-
uated in any of the 17 gastric cancers exhibiting LOH on 18q21.
However, polymorphisms at codon 201 (CGA/GGA) in exon 3
(Figure 2A) and at codon 951 (TTT/TTG) in exon 19 (Figure 2B)
were observed by PCR-SSCP. These polymorphisms have been
reported by Kong et al (1997). 
Methylation status and expression of DCC in primary
gastric cancers and corresponding normal gastric
mucosae 
45 (75%) of the 60 primary tumours and 43 (72%) of the 60 corre-
sponding normal gastric mucosae showed the presence of methyl-
ated DCC alleles (Figure 3). This methylation in non-cancerous
gastric mucosae may be an age-related phenomenon because
gastric mucosa DNAs from autopsies of a 21-week-old fetus and a
16-year-old female did not exhibit these methylated alleles (data
not shown). Methylated alleles were present in both the tumour
and normal pairs in 32 (53%), only in the tumour in 13 (22%), only
in the normal mucosa in 11 (18%), and in neither of the samples in
the remaining 4 (7%) of the 60 cases. 
Normal fundic and pyloric glands showed positive immunore-
activity against the DCC monoclonal antibody similar to a
previous report using the same antibody (Yoshida et al, 1998). In
primary tumors, 47 (78%) of 60 showed negative immunoreac-
tivity for DCC (Figure 4A). However, immunoreactivity in
intestinal metaplasia varied in each case, or even from area to area
within the same case (Figure 4B). Diminished DCC immunoreac-
tivity was observed in 40 (89%) of the 45 methylated and 7 (47%)
of the 15 unmethylated tumours (P < 0.01) (Table 2). 
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Figure 2 PCR-SSCP analysis of exon 3 (A) and exon 19 (B) in DCC.
Mobility shifts due to polymorphisms are clearly observed. One of
polymorphic bands exhibits marked reduction in intensity due to LOH in lanes
1, 2, 3 and 5 of panel A and in lanes 2 and 5 of panel B (arrowheads) 
Figure 3 MSP of 6 primary gastric cancers and their corresponding normal
gastric mucosae. Methylated alleles are present in the primary tumour (T) of
21Y, 22Y, 23Y and 24Y, and in the normal mucosa (N) of 21Y, 22Y, 23Y, 24Y
and 25Y. M, methylated allele; U, unmethylated allele; P, positive control; N,
negative control; and SM, size marker 
Figure 4 Immunohistochemical analysis of DCC in primary gastric cancer
and intestinal metaplasia. (A) Complete loss of DCC protein expression in
primary gastric cancer (left half), and strong DCC protein expression in
surrounding intestinal metaplasia (right half). (B) Reduced expression of
DCC protein in intestinal metaplasia (arrows) relative to surrounding pyloric
glands        
Table 2 Methylation status and expression of DCC in primary gastric cancer 
Methylation status DCC expression 
N* Lost or reduced (%) Expressed (%) 
Methylated 45 40 (89) 5 (11)a
Unmethylated 15 7 (47) 8 (53)b
*, number of tumours; avs. b, P < 0.01. DISCUSSION 
We have demonstrated that DCC is not structurally altered in
primary gastric cancers, although it is possible that some of our
cases may carry mutations in other exons than in those we have
studied. However, 78% (47/60) of the primary tumours exhibited
apparent loss of or reduction in DCC expression. This is the first
report investigating mutations of DCC in gastric cancer. Previous
reports have addressed infrequent mutations of this gene in
colorectal (Fearon et al, 1990; Cho et al, 1994), oesophageal
(Miyake et al, 1994) and neurogenic malignancies (Kong et al,
1997). All of those tumour types frequently lost DCC expression
and/or exhibited LOH at 18q21 (Miyake et al, 1994; Kong et al,
1997; Schmitt et al, 1998). In gastric cancer, frequent LOH on 18q
has been reported in differentiated cancers but was infrequent in
diffuse infiltrative lesions (Uchino et al, 1992; Yoshida et al,
1998). In the present study, LOH on 18q21 was infrequent in early
undifferentiated cancers, but frequent in both advanced undiffer-
entiated and differentiated cancers. Because a significant propor-
tion of differentiated gastric cancers progress to undifferentiated
ones (Ikeda et al, 1994; Endoh et al, 1999), advanced gastric
cancers of both histological types share common genetic alter-
ations. Our present results on LOH at 18q21 support the hypoth-
esis that the genetic pathways involved in differentiated and
undifferentiated gastric cancers are distinct at their early stages.
Similarly, infrequent mutations of p53 in early undifferentiated
gastric cancers have been reported (Wu et al, 1997). 
Loss of or reduction in DCC expression has been reported to
occur in 40% (Kataoka et al, 1995) or 52% (Yoshida et al, 1998) of
gastric cancers. The pronounced rates of diminished DCC expres-
sion in our study may have resulted from the method we employed
for the detection of DCC expression in primary tumours. There
were no significant differences of incidences observed between
loss of DCC expression and histological type or stage in our study. 
Hypermethylation of promoter regions near transcriptional start
sites correlated well with the loss or reduction observed in gene
expression (Baylin et al, 1998). Because the promoter sequence of
DCC has not yet been identified, we designed primers flanking the
start codon for MSP. Methylation originates in either flanking
region and spreads to include the promoter CpG islands near the
transcriptional start site (Graff et al, 1997). In the present study,
diminished DCC expression was observed not only in methylated
but also in unmethylated primary tumours. In addition, DCC was
expressed in some primary tumours exhibiting methylated alleles.
These discrepancies between methylation status and DCC expres-
sion might have resulted from differences in methylation status
between the heart of promoter CpG islands and the region we
studied. Methylation of only a small region of the hMLH1
promoter has been found to be sufficient to block expression
(Deng et al, 1999). It is also possible that other mechanisms which
interfere with DCC expression might be involved. Thus, methyla-
tion of DCC at the region studied did not always silence gene
expression. There is no evidence that shows this methylated
portion is involved in transcriptional activity, however, the signifi-
cant correlation between DCC methylation and loss of gene
expression in primary gastric cancers may suggest that this epige-
netic phenomenon plays a role in frequent loss of DCC expression. 
Methylation was also frequently observed in corresponding
non-cancerous gastric mucosae, although no methylated DCC
alleles were present in the stomach of a fetus and a 16-year-old
female (data not shown). For the ER and IGF2 genes, methylation
begins in the normal colonic mucosa as an age-related event and
progresses to hypermethylation in cancer (Ahuja et al, 1998). The
protection from de novo methylation by Sp1 elements may be lost
during aging (Ahuja et al, 1998). In a separate study, we found that
an APC promoter was usually methylated in the normal gastric
mucosae of elderly subjects (Tsuchiya et al, 2000) but was not
methylated in the fetus and the young female. In addition, the APC
promoter was not methylated in normal colonic mucosa (Hiltunen
et al, 1997). Therefore, age-related methylation might be modu-
lated by variable agents in a tissue-specific manner. In the present
study, we did not find a significant correlation between patient’s
age and DCC methylation status in normal gastric mucosae,
perhaps because most of the patients were older than 50 years of
age (range, 30–85; average, 65). Recently, frequent methylation of
the  hMLH1 promoter in colonic mucosae as well as in colon
cancers has been reported (Herman et al, 1998). Hypermethylation
of hMLH1 in colon cancers relative to normal colonic mucosae
correlated well with functional loss of hMLH1 assessed by the
presence of microsatellite instability (Kuismanen et al, 1999). We
found variable immunoreactivity for DCC in intestinal metaplasia,
which is commonly observed in the elderly Japanese population.
We speculate that methylation of DCC might initially occur in
intestinal metaplasia, and then progress to cancer, although the
relationship between methylation status and immunoreactivity for
DCC in intestinal metaplasia remains to be determined. Further
studies on intestinal metaplasia using microdissection will resolve
this issue. 
Because of the small number of tumours exhibiting LOH on
18q21, we failed to show significant correlation between methyla-
tion and expression of DCC in primary tumours exhibiting LOH
on 18q21, however, DCC expression was diminished more
frequently in methylated tumours than in unmethylated tumours
among 17 tumours exhibiting LOH on 18q21. p16 hypermethyla-
tion with concordant LOH on 9p21 has been reported in non-small
cell lung cancer (Kohno and Yokota, 1999). Therefore, it is
possible that LOH on 18q21 accompanied by methylation may
silence DCC expression in gastric cancers. It is also possible that
both alleles were affected by methylation in tumours retaining
both alleles. 
In conclusion, DCC is not mutated in gastric cancers, and
frequent loss of DCC expression might therefore result from an
epigenetic phenomenon. 
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